Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMX 001

Next Previous
Drug Profile

BMX 001

Alternative Names: BMX-001; BMX-001 free base; Manganese butoxyethyl pyridyl porphyrin - BioMimetix; MnTnBuOE-2-PyP5+

Latest Information Update: 21 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University
  • Developer BioMimetix; Duke University; University of Colorado at Denver; University of Nebraska Medical Center
  • Class Antineoplastics; Metalloporphyrins; Pyridines; Radioprotectives; Skin disorder therapies; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioma
  • Phase II Rectal cancer
  • Phase I/II Anal cancer; Brain metastases; Head and neck cancer
  • Preclinical Ovarian cancer
  • No development reported Atopic dermatitis

Most Recent Events

  • 20 Nov 2023 Safety and efficacy data from a phase II trial in glioma released by BioMimetix
  • 30 Oct 2023 BMX 001 is still in phase I/II trials for Anal cancer in USA (SC) (NCT03386500)
  • 30 Oct 2023 Preclinical trials in Ovarian cancer in USA (SC), before October 2023 (BioMimetix pipeline, October 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top